/PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,.
Operator: Good day, ladies and gentlemen and welcome to the Avid Bioservices Third Quarter Fiscal 2023 Financial Results Conference Call. As a reminder, this conference call maybe recorded.
Revolution Medicines Announces Pricing of $300 0 Million Public Offering of Common Stock streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Revolution Medicines (RVMD) Prices 13 64M Share Offering at $22/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
27.02.2023 - Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805 (KRASG12D) expected to begin clinical development .